|Bid||0.00000 x 0|
|Ask||0.00000 x 0|
|Day's Range||0.00000 - 0.00000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, British Columbia, Aug. 15, 2018-- Veritas Pharma Inc. is pleased to announce that it has signed a Memorandum of Understanding with IsCann Group Limited located in Be'er Tuvya, Israel with the ...
VANCOUVER, British Columbia, Aug. 13, 2018-- Veritas Pharma Inc. is pleased to announce that it has entered into a Memorandum of Understanding with the Chamber of Commerce, Industry, Services and Tourism ...
VANCOUVER, British Columbia, Aug. 08, 2018-- Veritas Pharma Inc. is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June ...
VANCOUVER, British Columbia, July 27, 2018-- Veritas Pharma Inc. is pleased to announce that effective June 25, 2018, it cancelled a total of 3,272,000 incentive stock options granted under the Company’ ...
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has signed an Intellectual Property Sharing Agreement (“Joint IP”) with Sativa Investments PLC (“Sativa”) (NEX:SATI), UK’s first medicinal cannabis investment fund. Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license.
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F) (“Veritas” or the “Company”) is pleased to announce that Mr. Filios Theodorou has been appointed as its business development agent in Cyprus. Currently, medical cannabis is legal in Cyprus, nonetheless doctors may only prescribe it to patients suffering from specific ailments, typically as a last resort and strictly for palliative care.
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Colombian medical cannabis company Foliumed S.A.S. (“Foliumed”). Under the terms of the MOU, Veritas and Foliumed will jointly conduct scientific research, undertake product development activities, and commercialize select medical cannabis products with the help of Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”).
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to provide a corporate update on its achievements, related scientific activities and growth strategies for the second quarter of fiscal 2018. Earlier this year, Veritas Pharma’s subsidiary Cannevert Therapeutics (“CTL”) signed an agreement with Puerto Rico’s Fundación de Investigación (“FDI”) Clinical Research to perform trials of its lead cannabis strain, CTL-X, to target pain.
In this article, I’m going to take a look at Veritas Pharma Inc’s (DB:2VP) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
CALGARY, Feb. 28, 2018 /CNW/ - BioCan Technologies Inc. ("BioCan" or the "Company") is pleased to announce that it has entered into a Memorandum of Understanding ("MoU") with Veritas Pharma Inc. ("Veritas") (CSE:VRT) (VRTHF) (Frankfurt: 2VP) to collaborate with Veritas on an exclusive basis to undertake further investigations of cannabis strains being developed by the research arm of Veritas, Cannevert Therapeutics Ltd. ("CTL"). The focus will be to optimize the genetics of their cannabis plants for scientific and clinical testing over the next two years. Pursuant to the MoU, definitive agreements in respect of the transactions contemplated in the MoU are expected to be executed by the parties on or before July 31, 2018. BioCan's CEO, Trevor Peters, stated "We are pleased to be working with Veritas and their scientific teams to develop medically relevant cannabis strains and cannabinoid formulations with optimal therapeutic properties.